Information  X 
Enter a valid email address

Verona Pharma PLC Ord 5P (VRP)

Date Time Source Announcement
20 May 2019 3:15 pm
GNW
Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
07 May 2019 12:51 pm
GNW
Result of AGM
  7:00 am
GNW
Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
  7:00 am
GNW
Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
02 May 2019 12:00 pm
GNW
Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
01 May 2019 7:00 am
GNW
Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update
  7:00 am
GNW
Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker
25 Apr 2019 12:07 pm
GNW
Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019
09 Apr 2019 7:00 am
GNW
Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine
04 Apr 2019 7:00 am
GNW
Grant of Options and RSUs and PDMR Dealings
26 Mar 2019 7:00 am
GNW
Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
25 Mar 2019 7:00 am
GNW
PDMR Dealing
22 Mar 2019 4:00 pm
GNW
2018 Annual Report and Accounts and Notice of AGM 
21 Mar 2019 7:00 am
GNW
Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director
20 Mar 2019 7:00 am
GNW
PDMR Dealing
11 Mar 2019 9:48 am
GNW
PDMR Dealing
07 Mar 2019 8:14 am
GNW
PDMR Dealing
05 Mar 2019 9:48 am
GNW
PDMR Dealing
04 Mar 2019 7:00 am
GNW
Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
28 Feb 2019 7:00 am
GNW
Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference
26 Feb 2019 7:00 am
GNW
Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update
20 Feb 2019 7:00 am
GNW
Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update
04 Feb 2019 7:00 am
GNW
Verona Pharma to Present at Upcoming Investor Conferences
14 Jan 2019 7:00 am
GNW
Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
09 Jan 2019 1:00 pm
GNW
Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554
17 Dec 2018 5:20 pm
GNW
Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
  7:00 am
GNW
Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
06 Nov 2018 7:00 am
GNW
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018
31 Oct 2018 7:00 am
GNW
Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment
30 Oct 2018 6:00 am
GNW
Verona Pharma to Announce Interim Results for Nine Months Ended September 30, 2018 and Provide Clinical Development Update
26 Oct 2018 10:12 am
GNW
Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis Conference
27 Sep 2018 7:00 am
GNW
Verona Pharma to Host Investor & Analyst R&D Forum on October 12, 2018
20 Sep 2018 4:49 pm
GNW
Issue of Shares & PDMR Announcement
13 Sep 2018 1:00 pm
GNW
Verona Pharma to Host Conference Call to Review Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD Presented at European Respiratory Society International Congress
12 Sep 2018 7:00 am
GNW
Verona Pharma to Present Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD at European Respiratory Society International Congress
06 Sep 2018 7:00 am
GNW
Verona Pharma Announces Publication of Key Paper on RPL554 in COPD in the European Respiratory Journal
10 Aug 2018 12:12 pm
GNW
Verona Pharma plc : PDMR Dealing & Issue of Shares
07 Aug 2018 7:00 am
GNW
Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018
01 Aug 2018 7:00 am
GNW
Verona Pharma Initiates Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment
26 Jul 2018 1:30 pm
GNW
Verona Pharma plc : Notice of Results
24 Jul 2018 1:30 pm
GNW
Verona Pharma to Present at 2018 Wedbush PacGrow Healthcare Conference
26 Jun 2018 5:22 pm
GNW
Verona Pharma plc : Result of General Meeting of Shareholders
04 Jun 2018 7:00 am
GNW
Verona Pharma's Shelf Registration Statement declared effective by SEC
31 May 2018 7:00 am
GNW
Verona Pharma plc : Block Listing Update
30 May 2018 1:30 pm
GNW
Verona Pharma to Present at Upcoming Investor Conferences
23 May 2018 7:00 am
GNW
Verona Pharma Files Shelf Registration Statement with SEC
22 May 2018 7:03 am
GNW
Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPD
09 May 2018 1:30 pm
GNW
Verona Pharma plc : Miscellaneous
08 May 2018 7:00 am
GNW
Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018
04 May 2018 1:30 pm
GNW
Verona Pharma to Present at Bio€quity Europe 2018
03 May 2018 8:31 am
GNW
Verona Pharma plc : Result of AGM
02 May 2018 1:30 pm
GNW
Verona Pharma to Announce Operational Update and Financial Results for First Quarter Ended March 31, 2018
11 Apr 2018 7:00 am
GNW
Verona Pharma Announces Departure of Chief Medical Officer
26 Mar 2018 7:00 am
GNW
Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD
15 Mar 2018 12:00 pm
GNW
Verona Pharma to Present at Upcoming Healthcare Investor Conferences
09 Mar 2018 5:30 pm
GNW
Verona Pharma plc: 2017 Annual Report and Accounts and Notice of AGM
  2:24 pm
GNW
Verona Pharma plc : Grant of Options and RSUs and PDMR Dealings
08 Mar 2018 1:38 pm
GNW
Verona Pharma plc : 1st Quarter Results
02 Mar 2018 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t